| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000012813 |
| Receipt No. | R000014967 |
| Official scientific title of the study | Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer. |
| Date of disclosure of the study information | 2014/01/20 |
| Last modified on | 2019/01/18 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer. | |
| Title of the study (Brief title) | Phase II trial as new adjuvant chemotherapy regimen for capecitabine | |
| Region |
|
|
| Condition | ||
| Condition | StageII(high risk) and stageIIIa resectable colorectal cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Safety and efficacy of new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Occurrence rate of side effect |
| Key secondary outcomes | Disease free survival, safety, proportion of treatments completed, quality of life. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Capecitabine 5-days on/ 2-days off schedule | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Histopathological diagnosis of stage II(high risk) and IIIa colorectal cancer
2.curable resection 3.more than 20 yeras old 4.ECOG Performance Status 0-2 5.WBC more than 3000/mm3, neutrophil more than 1500/mm3, Platelet more than 10x104/mm3, Hb more than 9g/dL, TBil less than 1.5mg/dL, AST and ALT less than 100IU/L Cr less than 1.5mg/dL, 6. it is possible to perform adjuvant chemotherapy within 8 weeks after tumor resection 7.informed consent |
|||
| Key exclusion criteria | 1.Pregnant female
2.It may be pregnant state female 3.Past history of malignant disease 4.There is uncontrolled cerebrovascular disease 5.There was serious allergy for fluorouracl related drug 6.There was allergy due to the lack of DPD 7.There is uncontrorable infection disease 8.It is difficult to intake oral food 9.Judgementof study controlled doctor |
|||
| Target sample size | 25 | |||
| Research contact person | |
| Name of lead principal investigator | Tsukasa Hotta |
| Organization | Wakayama Medical University,
School of Medicine |
| Division name | Second Department of Surgery |
| Address | 811-1, Kimiidera, Wakayama 641-8510, Japan |
| TEL | 073-441-0613 |
| hotta@wakayama-med.ac.jp | |
| Public contact | |
| Name of contact person | Tsukasa Hotta |
| Organization | Wakayama Medical University, School of Medicine |
| Division name | Second Department of Surgery |
| Address | 811-1, Kimiidera, Wakayama 641-8510, Japan |
| TEL | 073-441-0613 |
| Homepage URL | |
| hotta@wakayama-med.ac.jp | |
| Sponsor | |
| Institute | Tsukasa Hotta |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Wakayama Medical University,
School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000014967 |